141 related articles for article (PubMed ID: 18098147)
1. Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment.
Torres-Puente M; Cuevas JM; Jiménez-Hernández N; Bracho MA; García-Robles I; Carnicer F; del Olmo J; Ortega E; Moya A; González-Candelas F
J Med Virol; 2008 Feb; 80(2):247-53. PubMed ID: 18098147
[TBL] [Abstract][Full Text] [Related]
2. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.
Murayama M; Katano Y; Nakano I; Ishigami M; Hayashi K; Honda T; Hirooka Y; Itoh A; Goto H
J Med Virol; 2007 Jan; 79(1):35-40. PubMed ID: 17133546
[TBL] [Abstract][Full Text] [Related]
3. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes.
Frangeul L; Cresta P; Perrin M; Lunel F; Opolon P; Agut H; Huraux JM
Hepatology; 1998 Dec; 28(6):1674-9. PubMed ID: 9828234
[TBL] [Abstract][Full Text] [Related]
4. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
[TBL] [Abstract][Full Text] [Related]
5. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon.
Kobayashi M; Watanabe K; Ishigami M; Murase K; Ito H; Ukai K; Yano M; Takagi K; Hattori M; Kakumu S; Yoshioka K
Am J Gastroenterol; 2002 Apr; 97(4):988-98. PubMed ID: 12003437
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
[TBL] [Abstract][Full Text] [Related]
7. Sequence diversity of hepatitis C virus 6a within the extended interferon sensitivity-determining region correlates with interferon-alpha/ribavirin treatment outcomes.
Zhou DX; Chan PK; Zhang T; Tully DC; Tam JS
Virus Res; 2010 Oct; 153(1):44-9. PubMed ID: 20624431
[TBL] [Abstract][Full Text] [Related]
8. [Structural analysis of the PKR-binding region of HCV 1b samples from patients with chronic hepatitis C and the correlation with IFN-sensitivity].
Gervain J; Czibula A; Simon J; Kalmár T
Orv Hetil; 2003 Jun; 144(24):1179-84. PubMed ID: 12866147
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.
Hofmann WP; Zeuzem S; Sarrazin C
J Clin Virol; 2005 Feb; 32(2):86-91. PubMed ID: 15653410
[TBL] [Abstract][Full Text] [Related]
10. Mutations in interferon sensitivity-determining region of hepatitis C virus: its relation to change in viral load.
Terazawa Y; Yoshioka K; Kobayashi M; Watanabe K; Ishigami M; Yano M; Takagi K; Kakumu S
Am J Gastroenterol; 2000 Jul; 95(7):1781-7. PubMed ID: 10925985
[TBL] [Abstract][Full Text] [Related]
11. Method to detect substitutions in the interferon-sensitivity-determining region of hepatitis C virus 1b for prediction of response to interferon therapy.
Nishiguchi S; Ueda T; Itoh T; Enomoto M; Tanaka M; Tatsumi N; Fukuda K; Tamori A; Habu D; Takeda T; Otani S; Shiomi S
Hepatology; 2001 Jan; 33(1):241-7. PubMed ID: 11124842
[TBL] [Abstract][Full Text] [Related]
12. Association with 5'-untranslated region and response to interferon in chronic hepatitis C.
Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
Hepatogastroenterology; 2007; 54(75):854-7. PubMed ID: 17591078
[TBL] [Abstract][Full Text] [Related]
13. Lack of clinical evidence for involvement of hepatitis C virus interferon-alpha sensitivity-determining region variability in RNA-dependent protein kinase-mediated cellular antiviral responses.
Mihm S; Monazahian M; Grethe S; Meier V; Thomssen R; Ramadori G
J Med Virol; 2000 May; 61(1):29-36. PubMed ID: 10745229
[TBL] [Abstract][Full Text] [Related]
14. Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy.
Chayama K; Suzuki F; Tsubota A; Kobayashi M; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Takahashi N; Kinoshita M; Kumada H
Hepatology; 2000 Nov; 32(5):1138-44. PubMed ID: 11050067
[TBL] [Abstract][Full Text] [Related]
15. A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b.
Okamoto K; Akuta N; Kumada H; Kobayashi M; Matsuo Y; Tazawa H
J Virol Methods; 2007 Apr; 141(1):1-6. PubMed ID: 17184852
[TBL] [Abstract][Full Text] [Related]
16. [Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin].
Veillon P; Payan C; Gaudy C; Goudeau A; Lunel F
Pathol Biol (Paris); 2004 Nov; 52(9):505-10. PubMed ID: 15531113
[TBL] [Abstract][Full Text] [Related]
17. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2009 Jun; 81(6):1032-9. PubMed ID: 19382270
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions.
Schinkel J; Spaan WJ; Kroes AC
Antivir Ther; 2004 Apr; 9(2):275-86. PubMed ID: 15134190
[TBL] [Abstract][Full Text] [Related]
19. [Hepatitis C-virus --virus kinetics and resistance mechanisms].
Herrmann E; Sarrazin C
Z Gastroenterol; 2004 May; 42(5):387-96. PubMed ID: 15136939
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
